Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
45.2M
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
23.4M
-
Shares change
-
+3.72M
-
Total reported value, excl. options
-
$513M
-
Value change
-
+$75.3M
-
Number of buys
-
59
-
Number of sells
-
-14
-
Price
-
$21.94
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q4 2021
81 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.4M shares
of 45.2M outstanding shares and own 51.78% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (3.94M shares), BlackRock Inc. (2.09M shares), BVF INC/IL (2.01M shares), Deep Track Capital, LP (1.9M shares), JANUS HENDERSON GROUP PLC (1.65M shares), Octagon Capital Advisors LP (1.55M shares), Aquilo Capital Management, LLC (1.51M shares), VANGUARD GROUP INC (1.28M shares), STATE STREET CORP (1.26M shares), and ArrowMark Colorado Holdings LLC (1.11M shares).
This table shows the top 72 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.